Pros and cons of treating murine myasthenia gravis with anti-C1q antibody

Erdem Tüzün; Jing Li; S. Shamsher Saini; Huan Yang; Premkumar Christadoss

doi:10.1016/j.jneuroim.2006.10.014

Pros and cons of treating murine myasthenia gravis with anti-C1q antibody

Erdem Tüzün, Jing Li, S. Shamsher Saini, Huan Yang, Premkumar Christadoss

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

To test the feasibility of classical complement pathway manipulation in experimental autoimmune myasthenia gravis (EAMG) treatment, C57BL/6 (B6) and RIIIS/J mice with EAMG were treated with 10 μg or 100 μg of anti-C1q Ab or isotype Ab. Treatment with 10 μg anti-C1q Ab significantly reduced the clinical severity, decreased lymph node cell IL-6 production and T cell populations. Conversely, administration of 100 μg anti-C1q Ab caused harmful side effects such as increased serum anti-acetylcholine receptor antibody, immune complex, C3 and lymph node B cell levels and kidney C3 and IgG deposits, which reduced the treatment efficacy.

Original language	English (US)
Pages (from-to)	167-176
Number of pages	10
Journal	Journal of Neuroimmunology
Volume	182
Issue number	1-2
DOIs	https://doi.org/10.1016/j.jneuroim.2006.10.014
State	Published - Jan 2007
Externally published	Yes

Keywords

Autoimmunity
C1q
Classical complement pathway
Myasthenia gravis

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Neurology
Clinical Neurology

Access to Document

10.1016/j.jneuroim.2006.10.014

Cite this

@article{5383f48dbf1f481585af332de908fcbb,

title = "Pros and cons of treating murine myasthenia gravis with anti-C1q antibody",

abstract = "To test the feasibility of classical complement pathway manipulation in experimental autoimmune myasthenia gravis (EAMG) treatment, C57BL/6 (B6) and RIIIS/J mice with EAMG were treated with 10 μg or 100 μg of anti-C1q Ab or isotype Ab. Treatment with 10 μg anti-C1q Ab significantly reduced the clinical severity, decreased lymph node cell IL-6 production and T cell populations. Conversely, administration of 100 μg anti-C1q Ab caused harmful side effects such as increased serum anti-acetylcholine receptor antibody, immune complex, C3 and lymph node B cell levels and kidney C3 and IgG deposits, which reduced the treatment efficacy.",

keywords = "Autoimmunity, C1q, Classical complement pathway, Myasthenia gravis",

author = "Erdem T{\"u}z{\"u}n and Jing Li and Saini, {S. Shamsher} and Huan Yang and Premkumar Christadoss",

note = "Funding Information: This study is supported by NIHR21A1049995, Muscular Dystrophy Association, and Advanced Technology Program of Texas Higher Education Coordinating Board. ",

year = "2007",

month = jan,

doi = "10.1016/j.jneuroim.2006.10.014",

language = "English (US)",

volume = "182",

pages = "167--176",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier B.V.",

number = "1-2",

}

TY - JOUR

T1 - Pros and cons of treating murine myasthenia gravis with anti-C1q antibody

AU - Tüzün, Erdem

AU - Li, Jing

AU - Saini, S. Shamsher

AU - Yang, Huan

AU - Christadoss, Premkumar

N1 - Funding Information: This study is supported by NIHR21A1049995, Muscular Dystrophy Association, and Advanced Technology Program of Texas Higher Education Coordinating Board.

PY - 2007/1

Y1 - 2007/1

N2 - To test the feasibility of classical complement pathway manipulation in experimental autoimmune myasthenia gravis (EAMG) treatment, C57BL/6 (B6) and RIIIS/J mice with EAMG were treated with 10 μg or 100 μg of anti-C1q Ab or isotype Ab. Treatment with 10 μg anti-C1q Ab significantly reduced the clinical severity, decreased lymph node cell IL-6 production and T cell populations. Conversely, administration of 100 μg anti-C1q Ab caused harmful side effects such as increased serum anti-acetylcholine receptor antibody, immune complex, C3 and lymph node B cell levels and kidney C3 and IgG deposits, which reduced the treatment efficacy.

AB - To test the feasibility of classical complement pathway manipulation in experimental autoimmune myasthenia gravis (EAMG) treatment, C57BL/6 (B6) and RIIIS/J mice with EAMG were treated with 10 μg or 100 μg of anti-C1q Ab or isotype Ab. Treatment with 10 μg anti-C1q Ab significantly reduced the clinical severity, decreased lymph node cell IL-6 production and T cell populations. Conversely, administration of 100 μg anti-C1q Ab caused harmful side effects such as increased serum anti-acetylcholine receptor antibody, immune complex, C3 and lymph node B cell levels and kidney C3 and IgG deposits, which reduced the treatment efficacy.

KW - Autoimmunity

KW - C1q

KW - Classical complement pathway

KW - Myasthenia gravis

UR - http://www.scopus.com/inward/record.url?scp=33845884294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845884294&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2006.10.014

DO - 10.1016/j.jneuroim.2006.10.014

M3 - Article

C2 - 17137637

AN - SCOPUS:33845884294

SN - 0165-5728

VL - 182

SP - 167

EP - 176

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

IS - 1-2

ER -

Pros and cons of treating murine myasthenia gravis with anti-C1q antibody

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this